Literature DB >> 9391692

Ethnicity and antipsychotic response.

E J Frackiewicz1, J J Sramek, J M Herrera, N M Kurtz, N R Cutler.   

Abstract

OBJECTIVE: To review the data generated by studies examining interethnic/racial differences in response to antipsychotics. DATA SOURCES: A MEDLINE search (1966-1996) identified all articles examining differences in antipsychotic response among Caucasians, Asians, Hispanics, and African-Americans, as well as articles evaluating postulated mechanisms for these differences. STUDY SELECTION: All abstracts, studies, and review articles were evaluated. DATA SYNTHESIS: Ethnic/racial differences in response to antipsychotic medications have been reported and may be due to genetics, kinetic variations, dietary or environmental factors, or variations in the prescribing practices of clinicians. Studies suggest that Asians may respond to lower doses of antipsychotics due to pharmacokinetic and pharmacodynamic differences. Research relevant to African-Americans is limited, but some studies suggest that differences in this group may be due to clinician biases and prescribing practices, rather than to pharmacokinetic or pharmacodynamic variability.
CONCLUSIONS: Future research directed at validating the hypotheses that different ethnic/racial groups show variations in response to antipsychotics should focus on homogeneous ethnic groups, use recent advances in pharmacogenetic testing, and control for such variables as observer bias, gender, disease chronicity, dietary and environmental factors, and exposure to enzyme-inducing and -inhibiting agents. Clinicians should be aware that potential interethnic/racial differences in pharmacodynamics and pharmacokinetics may exist that can alter response to antipsychotics.

Mesh:

Substances:

Year:  1997        PMID: 9391692     DOI: 10.1177/106002809703101114

Source DB:  PubMed          Journal:  Ann Pharmacother        ISSN: 1060-0280            Impact factor:   3.154


  19 in total

Review 1.  The challenges of psychopharmacogenetics.

Authors:  M Catalano
Journal:  Am J Hum Genet       Date:  1999-09       Impact factor: 11.025

Review 2.  Genetics and psychopharmacology: prospects for individualized treatment.

Authors:  Charles U Nnadi; Joseph F Goldberg; Anil K Malhotra
Journal:  Essent Psychopharmacol       Date:  2005

3.  Association of two DRD2 gene polymorphisms with acute and tardive antipsychotic-induced movement disorders in young Caucasian patients.

Authors:  Jeroen P Koning; Jelle Vehof; Huibert Burger; Bob Wilffert; Asmar Al Hadithy; Behrooz Alizadeh; Peter N van Harten; Harold Snieder
Journal:  Psychopharmacology (Berl)       Date:  2011-07-13       Impact factor: 4.530

Review 4.  Pharmacogenetics in psychiatry: are we ready for widespread clinical use?

Authors:  Maria J Arranz; Shitij Kapur
Journal:  Schizophr Bull       Date:  2008-08-27       Impact factor: 9.306

5.  Structural models describing placebo treatment effects in schizophrenia and other neuropsychiatric disorders.

Authors:  Venkatesh Pilla Reddy; Magdalena Kozielska; Martin Johnson; An Vermeulen; Rik de Greef; Jing Liu; Geny M M Groothuis; Meindert Danhof; Johannes H Proost
Journal:  Clin Pharmacokinet       Date:  2011-07       Impact factor: 6.447

6.  Access to new medications to treat schizophrenia.

Authors:  Tami L Mark; Riad Dirani; Eric Slade; Patricia A Russo
Journal:  J Behav Health Serv Res       Date:  2002-02       Impact factor: 1.505

Review 7.  Pharmacogenetics of response to antipsychotics in patients with schizophrenia.

Authors:  Maria J Arranz; Margarita Rivera; Janet C Munro
Journal:  CNS Drugs       Date:  2011-11-01       Impact factor: 5.749

8.  Genetic Variants Within Molecular Targets of Antipsychotic Treatment: Effects on Treatment Response, Schizophrenia Risk, and Psychopathological Features.

Authors:  Marco Calabrò; Stefano Porcelli; Concetta Crisafulli; Sheng-Min Wang; Soo-Jung Lee; Changsu Han; Ashwin A Patkar; Prakash S Masand; Diego Albani; Ilaria Raimondi; Gianluigi Forloni; Sofia Bin; Carlotta Cristalli; Vilma Mantovani; Chi-Un Pae; Alessandro Serretti
Journal:  J Mol Neurosci       Date:  2017-11-21       Impact factor: 3.444

9.  The effect of race-ethnicity on the comparative effectiveness of clozapine among Medicaid beneficiaries.

Authors:  Marcela Horvitz-Lennon; Julie M Donohue; Judith R Lave; Margarita Alegría; Sharon-Lise T Normand
Journal:  Psychiatr Serv       Date:  2013-03-01       Impact factor: 3.084

10.  Long-acting risperidone injection: efficacy, safety, and cost-effectiveness of the first long-acting atypical antipsychotic.

Authors:  Pierre Chue
Journal:  Neuropsychiatr Dis Treat       Date:  2007-02       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.